Influenza Vaccine in HIV Study

A Comparison of Immune Responses to the Licensed Trivalent Inactivated Influenza Vaccine in HIV-positive and HIV-negative Subjects

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02632578

Enrollment

Registered

2015-12-16

Start date

2015-02-28

Completion date

2015-12-31

Last updated

2015-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza, Human

Brief summary

The aims of this study are: 1. to investigate if HIV infection alters the antibody responses to influenza and 2. to assess the ability of licensed influenza vaccine to induce functional non-neutralising antibodies in HIV-infected and HIV-uninfected subjects.

Interventions

BIOLOGICAL2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)

Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* HIV-1 positive by licensed diagnostic test (for HIV-positive group only) * Planning to receive the seasonal influenza vaccine outside the study * Provision of written informed consent

Exclusion criteria

* Previous allergy to influenza vaccination * Pregnancy or planning to become pregnant * Unwilling or unable to provide blood samples

Design outcomes

Primary

Measure	Time frame
Anti-influenza antibody responses in plasma with Fc-mediated functions	Four weeks after influenza vaccination

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026